表紙
市場調查報告書
商品編碼
1036109

急性病毒性鼻竇炎治療市場:全球產業分析·市場規模·佔有率·成長·趨勢·預測(2021年∼2031年)

Acute Viral Rhinosinusitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

出版日期: | 出版商: Transparency Market Research | 英文 254 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球急性病毒性鼻竇炎治療市場相關調查,市場概要,治療藥·給藥途徑·流通管道·各感染疾病類型的市場規模的預測,市場成長的推動要素及阻礙因素,市場機會分析,各地區的詳細趨勢,競爭情形,主要企業簡介等資訊。

目錄

第1章 序文

第2章 假設與調查手法

第3章 摘要整理:全球急性病毒性鼻竇炎治療市場

第4章 市場概要

  • 簡介·概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 全球急性病毒性鼻竇炎治療市場分析與預測

第5章 市場預測

  • 臨床試驗及法規當局的認證分析
  • 已批准品牌/產品與
  • COVID-19疫情對產業的影響(價值鏈及短期/中期/長期的影響)
  • 技術的進步
  • 疾病得病率和發生率

第6章 全球急性病毒性鼻竇炎治療市場分析與預測:各治療藥物

  • 簡介和定義
  • 全球急性病毒性鼻竇炎治療的市場規模的預測:各治療藥物
    • 生理食鹽水滴鼻劑
    • 鼻用皮質類固醇
    • 充血消除藥
    • NSAID
  • 全球急性病毒性鼻竇炎治療市場魅力分析:各治療藥物

第7章 全球急性病毒性鼻竇炎治療市場分析與預測:各給藥途徑

  • 簡介和定義
  • 全球急性病毒性鼻竇炎治療的市場規模的預測:各給藥途徑
  • 全球急性病毒性鼻竇炎治療市場魅力分析:各給藥途徑

第8章 全球急性病毒性鼻竇炎治療市場分析與預測:各流通管道

  • 簡介和定義
  • 全球急性病毒性鼻竇炎治療的市場規模的預測:各流通管道
  • 全球急性病毒性鼻竇炎治療市場魅力分析:各流通管道

第9章 全球急性病毒性鼻竇炎治療市場分析與預測:各感染疾病類型

  • 簡介和定義
  • 全球急性病毒性鼻竇炎治療的市場規模的預測:各感染疾病類型
    • 鼻病毒(小核醣核酸病毒)
    • 非鼻病毒
  • 全球急性病毒性鼻竇炎治療市場魅力分析:各感染疾病類型

第10章 全球急性病毒性鼻竇炎治療市場分析與預測:各地區

  • 主要調查結果
  • 全球急性病毒性鼻竇炎治療的市場規模的預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 全球急性病毒性鼻竇炎治療市場魅力分析:各地區

第11章 北美的急性病毒性鼻竇炎治療市場分析與預測

  • 簡介
  • 北美的急性病毒性鼻竇炎治療的市場規模的預測:各治療藥物
  • 北美的急性病毒性鼻竇炎治療的市場規模的預測:各給藥途徑
  • 北美的急性病毒性鼻竇炎治療的市場規模的預測:各流通管道
  • 北美的急性病毒性鼻竇炎治療的市場規模的預測:各感染疾病類型
  • 北美的急性病毒性鼻竇炎治療的市場規模的預測:各國
    • 美國
    • 加拿大
  • 北美的急性病毒性鼻竇炎治療市場魅力分析:各市場區隔

第12章 歐洲的急性病毒性鼻竇炎治療市場分析與預測

第13章 亞太地區的急性病毒性鼻竇炎治療市場分析與預測

第14章 南美的急性病毒性鼻竇炎治療市場分析與預測

第15章 中東·非洲的急性病毒性鼻竇炎治療市場分析與預測

第16章 競爭情形

  • 市場情況分析:各企業(2020年)
  • 企業簡介
    • Sun Pharmaceutical Industries, Inc.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Fresenius Kabi USA, LLC.
    • Dr. Reddy's Laboratories, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Abbott Laboratories
    • Bayer AG
    • Eli Lilly And Company
    • Bristol-Myers Squibb
    • Merck &Co, Inc.
    • AstraZeneca Plc
    • Amneal Pharmaceuticals LLC
    • GlaxoSmithKline plc
    • Aurobindo Pharma
    • Hikma Pharmaceuticals plc
    • Wockhardt
    • Mylan NV
目錄
Product Code: TMRGL82764

Acute Viral Rhinosinusitis Treatment Market - Scope of Report

TMR's report on the global acute viral rhinosinusitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the global acute viral rhinosinusitis treatment market for the period of 2017-2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute viral rhinosinusitis treatment market from 2021 to 2031.

The report has been prepared after extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global acute viral rhinosinusitis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global acute viral rhinosinusitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global acute viral rhinosinusitis treatment market. These serve as valuable tools for existing market players as well as entities interested in participating in the global acute viral rhinosinusitis treatment market.

The report also delves into the competitive landscape of the global acute viral rhinosinusitis treatment market. Key players operating in the global acute viral rhinosinusitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute viral rhinosinusitis treatment market that have been profiled in this report.

Key Questions Answered in Acute Viral Rhinosinusitis Treatment Report

What is the sales/revenue generated by acute viral rhinosinusitis treatment products across all regions during the forecast period?

What are the opportunities in the global acute viral rhinosinusitis treatment market?

What are major drivers, restraints, opportunities, and threats in the global market?

Which region is set to expand at the fastest CAGR during the forecast period?

Which treatment product segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?

What are the market positions of different companies operating in the global market?

Acute Viral Rhinosinusitis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute viral rhinosinusitis treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of treatments.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute viral rhinosinusitis treatment market in terms of treatment, route of administration, distribution channel, infection type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global acute viral rhinosinusitis treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Viral Rhinosinusitis Treatment Market

4. Market Overview

  • 4.1. Introduction & Overview
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
  • 4.3. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, 2017-2031

5. Market Outlook

  • 5.1. Clinical Trials & Regulatory Approvals Analysis
  • 5.2. List of Brand / Product Approved
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
  • 5.4. Technological Advancements
  • 5.5. Disease Prevalence & Incidence

6. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Treatment

  • 6.1. Introduction & Definition
  • 6.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 6.2.1. Saline Nasal Spray
    • 6.2.2. Nasal Corticosteroids
      • 6.2.2.1. Fluticasone
      • 6.2.2.2. Budesonide
      • 6.2.2.3. Mometasone
      • 6.2.2.4. Others
    • 6.2.3. Decongestants
      • 6.2.3.1. Topical Decongestants
      • 6.2.3.2. Systemic Decongestants
    • 6.2.4. NSAIDs
      • 6.2.4.1. Acetaminophen
      • 6.2.4.2. Ibuprofen
      • 6.2.4.3. Aspirin
      • 6.2.4.4. Others
  • 6.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration

7. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
    • 7.2.1. Acute Viral Rhinosinusitis Treatment
      • 7.2.1.1. Topical
      • 7.2.1.2. Nasal
      • 7.2.1.3. Oral
      • 7.2.1.4. Injectable
  • 7.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration

8. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • 8.2.1. Acute Viral Rhinosinusitis Treatment
      • 8.2.1.1. Online Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Hospital Pharmacies
  • 8.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Infection Type

  • 9.1. Introduction & Definition
  • 9.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 9.2.1. Rhinovirus (Picornavirus)
    • 9.2.2. Non-Rhinovirus
      • 9.2.2.1. Influenza
      • 9.2.2.2. Enterovirus
      • 9.2.2.3. Adenovirus
      • 9.2.2.4. Others
  • 9.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Infection Type

10. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Region

11. North America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 11.2.1. Saline Nasal Spray
    • 11.2.2. Nasal Corticosteroids
      • 11.2.2.1. Fluticasone
      • 11.2.2.2. Budesonide
      • 11.2.2.3. Mometasone
      • 11.2.2.4. Others
    • 11.2.3. Decongestants
      • 11.2.3.1. Topical Decongestants
      • 11.2.3.2. Systemic Decongestants
    • 11.2.4. NSAIDs
      • 11.2.4.1. Acetaminophen
      • 11.2.4.2. Ibuprofen
      • 11.2.4.3. Aspirin
      • 11.2.4.4. Others
    • 11.2.5. Others
  • 11.3. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Acute Viral Rhinosinusitis Treatment
      • 11.3.1.1. Topical
      • 11.3.1.2. Nasal
      • 11.3.1.3. Oral
      • 11.3.1.4. Injectable
  • 11.4. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Acute Viral Rhinosinusitis Treatment
      • 11.4.1.1. Online Pharmacies
      • 11.4.1.2. Retail Pharmacies
      • 11.4.1.3. Hospital Pharmacies
  • 11.5. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 11.5.1. Rhinovirus (Picornavirus)
    • 11.5.2. Non-Rhinovirus
      • 11.5.2.1. Influenza
      • 11.5.2.2. Enterovirus
      • 11.5.2.3. Adenovirus
      • 11.5.2.4. Others
  • 11.6. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
    • 11.7.1. By Treatment
    • 11.7.2. By Route of Administration
    • 11.7.3. By Distribution Channel
    • 11.7.4. Infection Type
    • 11.7.5. By Country

12. Europe Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 12.2.1. Saline Nasal Spray
    • 12.2.2. Nasal Corticosteroids
      • 12.2.2.1. Fluticasone
      • 12.2.2.2. Budesonide
      • 12.2.2.3. Mometasone
      • 12.2.2.4. Others
    • 12.2.3. Decongestants
      • 12.2.3.1. Topical Decongestants
      • 12.2.3.2. Systemic Decongestants
    • 12.2.4. NSAIDs
      • 12.2.4.1. Acetaminophen
      • 12.2.4.2. Ibuprofen
      • 12.2.4.3. Aspirin
      • 12.2.4.4. Others
    • 12.2.5. Others
  • 12.3. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
      • 12.3.1.1. Topical
      • 12.3.1.2. Nasal
      • 12.3.1.3. Oral
      • 12.3.1.4. Injectable
  • 12.4. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
      • 12.4.1.1. Online Pharmacies
      • 12.4.1.2. Retail Pharmacies
      • 12.4.1.3. Hospital Pharmacies
  • 12.5. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 12.5.1. Rhinovirus (Picornavirus)
    • 12.5.2. Non-Rhinovirus
      • 12.5.2.1. Influenza
      • 12.5.2.2. Enterovirus
      • 12.5.2.3. Adenovirus
      • 12.5.2.4. Others
  • 12.6. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Europe Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
    • 12.7.1. By Treatment
    • 12.7.2. By Route of Administration
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Infection Type
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 13.2.1. Saline Nasal Spray
    • 13.2.2. Nasal Corticosteroids
      • 13.2.2.1. Fluticasone
      • 13.2.2.2. Budesonide
      • 13.2.2.3. Mometasone
      • 13.2.2.4. Others
    • 13.2.3. Decongestants
      • 13.2.3.1. Topical Decongestants
      • 13.2.3.2. Systemic Decongestants
    • 13.2.4. NSAIDs
      • 13.2.4.1. Acetaminophen
      • 13.2.4.2. Ibuprofen
      • 13.2.4.3. Aspirin
      • 13.2.4.4. Others
    • 13.2.5. Others
  • 13.3. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
      • 13.3.1.1. Topical
      • 13.3.1.2. Nasal
      • 13.3.1.3. Oral
      • 13.3.1.4. Injectable
  • 13.4. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
      • 13.4.1.1. Online Pharmacies
      • 13.4.1.2. Retail Pharmacies
      • 13.4.1.3. Hospital Pharmacies
  • 13.5. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 13.5.1. Rhinovirus (Picornavirus)
    • 13.5.2. Non-Rhinovirus
      • 13.5.2.1. Influenza
      • 13.5.2.2. Enterovirus
      • 13.5.2.3. Adenovirus
      • 13.5.2.4. Others
  • 13.6. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
    • 13.7.1. By Treatment
    • 13.7.2. By Route of Administration
    • 13.7.3. By Distribution Channel
    • 13.7.4. Infection Type
    • 13.7.5. By Country/Sub-region

14. Latin America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 14.2.1. Saline Nasal Spray
    • 14.2.2. Nasal Corticosteroids
      • 14.2.2.1. Fluticasone
      • 14.2.2.2. Budesonide
      • 14.2.2.3. Mometasone
      • 14.2.2.4. Others
    • 14.2.3. Decongestants
      • 14.2.3.1. Topical Decongestants
      • 14.2.3.2. Systemic Decongestants
    • 14.2.4. NSAIDs
      • 14.2.4.1. Acetaminophen
      • 14.2.4.2. Ibuprofen
      • 14.2.4.3. Aspirin
      • 14.2.4.4. Others
    • 14.2.5. Others
  • 14.3. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
      • 14.3.1.1. Topical
      • 14.3.1.2. Nasal
      • 14.3.1.3. Oral
      • 14.3.1.4. Injectable
  • 14.4. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
      • 14.4.1.1. Online Pharmacies
      • 14.4.1.2. Retail Pharmacies
      • 14.4.1.3. Hospital Pharmacies
  • 14.5. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 14.5.1. Rhinovirus (Picornavirus)
    • 14.5.2. Non-Rhinovirus
      • 14.5.2.1. Influenza
      • 14.5.2.2. Enterovirus
      • 14.5.2.3. Adenovirus
      • 14.5.2.4. Others
  • 14.6. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Latin America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
    • 14.7.1. By Treatment
    • 14.7.2. By Route of Administration
    • 14.7.3. By Distribution Channel
    • 14.7.4. Infection Type
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
    • 15.2.1. Saline Nasal Spray
    • 15.2.2. Nasal Corticosteroids
      • 15.2.2.1. Fluticasone
      • 15.2.2.2. Budesonide
      • 15.2.2.3. Mometasone
      • 15.2.2.4. Others
    • 15.2.3. Decongestants
      • 15.2.3.1. Topical Decongestants
      • 15.2.3.2. Systemic Decongestants
    • 15.2.4. NSAIDs
      • 15.2.4.1. Acetaminophen
      • 15.2.4.2. Ibuprofen
      • 15.2.4.3. Aspirin
      • 15.2.4.4. Others
    • 15.2.5. Others
  • 15.3. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
      • 15.3.1.1. Topical
      • 15.3.1.2. Nasal
      • 15.3.1.3. Oral
      • 15.3.1.4. Injectable
  • 15.4. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • 15.4.1. Acute Viral Rhinosinusitis Treatment
      • 15.4.1.1. Online Pharmacies
      • 15.4.1.2. Retail Pharmacies
      • 15.4.1.3. Hospital Pharmacies
  • 15.5. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
    • 15.5.1. Rhinovirus (Picornavirus)
    • 15.5.2. Non-Rhinovirus
      • 15.5.2.1. Influenza
      • 15.5.2.2. Enterovirus
      • 15.5.2.3. Adenovirus
      • 15.5.2.4. Others
  • 15.6. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
    • 15.7.1. By Treatment
    • 15.7.2. By Route of Administration
    • 15.7.3. By Distribution Channel
    • 15.7.4. By Infection Type
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Position Analysis, by Company, 2020
  • 16.2. Company Profiles
    • 16.2.1. Sun Pharmaceutical Industries, Inc.
      • 16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.1.2. Growth Strategies
      • 16.2.1.3. SWOT Analysis
    • 16.2.2. Pfizer Inc.
      • 16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.2.2. Growth Strategies
      • 16.2.2.3. SWOT Analysis
    • 16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
      • 16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.3.2. Growth Strategies
      • 16.2.3.3. SWOT Analysis
    • 16.2.4. Fresenius Kabi USA, LLC.
      • 16.2.4.1. Company Overview (HQ, Business Segments)
      • 16.2.4.2. Growth Strategies
      • 16.2.4.3. SWOT Analysis
    • 16.2.5. Dr. Reddy's Laboratories, Inc.
      • 16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.5.2. Growth Strategies
      • 16.2.5.3. SWOT Analysis
    • 16.2.6. Novartis AG
      • 16.2.6.1. Company Overview (HQ, Business Segments)
      • 16.2.6.2. Growth Strategies
      • 16.2.6.3. SWOT Analysis
    • 16.2.7. Teva Pharmaceutical Industries Ltd.
      • 16.2.7.1. Company Overview (HQ, Business Segments)
      • 16.2.7.2. Growth Strategies
      • 16.2.7.3. SWOT Analysis
    • 16.2.8. Sanofi
      • 16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.8.2. Growth Strategies
      • 16.2.8.3. SWOT Analysis
    • 16.2.9. Abbott Laboratories
      • 16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.9.2. Growth Strategies
      • 16.2.9.3. SWOT Analysis
    • 16.2.10. Bayer AG
      • 16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.10.2. Growth Strategies
      • 16.2.10.3. SWOT Analysis
    • 16.2.11. Eli Lilly And Company
      • 16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.11.2. Growth Strategies
      • 16.2.11.3. SWOT Analysis
    • 16.2.12. Bristol-Myers Squibb
      • 16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.12.2. Growth Strategies
      • 16.2.12.3. SWOT Analysis
    • 16.2.13. Merck & Co, Inc.
      • 16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.13.2. Growth Strategies
      • 16.2.13.3. SWOT Analysis
    • 16.2.14. AstraZeneca Plc
      • 16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.14.2. Growth Strategies
      • 16.2.14.3. SWOT Analysis
    • 16.2.15. Amneal Pharmaceuticals LLC
      • 16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.15.2. Growth Strategies
      • 16.2.15.3. SWOT Analysis
    • 16.2.16. GlaxoSmithKline plc
      • 16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.16.2. Growth Strategies
      • 16.2.16.3. SWOT Analysis
    • 16.2.17. Aurobindo Pharma
      • 16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.17.2. Growth Strategies
      • 16.2.17.3. SWOT Analysis
    • 16.2.18. Hikma Pharmaceuticals plc
      • 16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.18.2. Growth Strategies
      • 16.2.18.3. SWOT Analysis
    • 16.2.19. Wockhardt
      • 16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.19.2. Growth Strategies
      • 16.2.19.3. SWOT Analysis
    • 16.2.20. Mylan N.V.
      • 16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.20.2. Growth Strategies
      • 16.2.20.3. SWOT Analysis

List of Tables

  • Table 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 02: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 03: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031
  • Table 09: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 10: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 12: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 13: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 14: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 15: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 18: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031
  • Table 19: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 20: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 21: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 22: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 23: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 24: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 25: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 26: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 27: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031
  • Table 28: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 29: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 30: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 31: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 32: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 33: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 34: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 35: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 36: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031
  • Table 37: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 38: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 39: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 40: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 41: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 42: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 43: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 44: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 45: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031
  • Table 46: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 47: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 48: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017-2031
  • Table 49: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017-2031
  • Table 50: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017-2031
  • Table 51: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 52: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 53: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017-2031
  • Table 54: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017-2031

List of Figures

  • Figure 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 03: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Saline Nasal Spray, 2017-2031
  • Figure 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal Corticosteroids, 2017-2031
  • Figure 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Decongestants, 2017-2031
  • Figure 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by NSAIDs, 2017-2031
  • Figure 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Others, 2017-2031
  • Figure 09: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 10: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 11: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Topical, 2017-2031
  • Figure 12: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal, 2017-2031
  • Figure 13: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Oral, 2017-2031
  • Figure 14: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Injectable, 2017-2031
  • Figure 15: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 16: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 17: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 18: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 19: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 20: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 21: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031
  • Figure 22: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Rhinovirus (Picornavirus), 2017-2031
  • Figure 23: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Non-rhinovirus, 2017-2031
  • Figure 24: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Region, 2020 and 2031
  • Figure 25: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 26: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 27: North America Acute Viral Rhinosinusitis Market Value Share, by Country, 2020 and 2031
  • Figure 28: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country, 2021-2031
  • Figure 29: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 30: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 31: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 32: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 33: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 34: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 35: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 36: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031
  • Figure 37: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 38: Europe Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
  • Figure 39: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 40: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 41: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 42: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 43: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 44: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 45: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 46: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 47: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031
  • Figure 48: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 49: Asia Pacific Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
  • Figure 50: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 51: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 52: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 53: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 54: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 55: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 56: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 57: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 58: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031
  • Figure 59: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 60: Latin America Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
  • Figure 61: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 62: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 63: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 64: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 65: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 66: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 67: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 68: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 69: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031
  • Figure 70: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 71: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
  • Figure 72: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 73: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
  • Figure 74: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021-2031
  • Figure 75: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 76: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 77: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 78: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 79: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
  • Figure 80: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021-2031